← Eichor
Condition: Breast Cancer Recurrence Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Breast Cancer Recurrence

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac
Phase 3 · 590 location(s) · SWOG Cancer Research Network · NCT03418961KORTUC Phase II - Intra-tumoural Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer
Phase 2 · 10 location(s) · Institute of Cancer Research, United Kingdom · NCT03946202Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
Phase 1 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT06347068A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurr
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07520760A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who H
Phase 3 · 1 location(s) · Jiangsu Alphamab Biopharmaceuticals Co., Ltd · NCT07533123HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
Phase 1 · 1 location(s) · Jiangsu Hansoh Pharmaceutical Co., Ltd. · NCT06769425A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer
Phase 1/Phase 2 · 1 location(s) · BriaCell Therapeutics Corporation · NCT06471673A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
Phase 3 · 2 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT07111832Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer
Phase 2 · 14 location(s) · Yukinori Ozaki · NCT06976944Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended En
Phase N/A · 12 location(s) · Shengjing Hospital · NCT04476485Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
NA · 19 location(s) · University Health Network, Toronto · NCT05592938Chronic Toxicities Related to Treatment in Patients With Localized Cancer
NA · 1 location(s) · UNICANCER · NCT01993498A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in
Phase N/A · 284 location(s) · Novartis Pharmaceuticals · NCT06830720A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.
NA · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06371274A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Phase 3 · 709 location(s) · AstraZeneca · NCT05774951Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer
Phase 1/Phase 2 · 1 location(s) · Nagoya City University · NCT07164976Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Canc
Phase 1 · 4 location(s) · Emory University · NCT06324240177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
Phase 2 · 1 location(s) · OHSU Knight Cancer Institute · NCT04529044Cognitive Behavioral Therapy for Fear of Cancer Recurrence in Women With BRCA1/2 Gene
NA · 1 location(s) · CHU de Quebec-Universite Laval · NCT06817694Neratinib in Combination With Ruxolitinib in Patients With mTNBC
EARLY_Phase 1 · 1 location(s) · Baylor Research Institute · NCT06008275CRYoablation for Small Tumors As Local Treatment - SIX Trial
Phase 3 · 2 location(s) · Hospital do Coracao · NCT06839001Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial
NA · 2 location(s) · Wake Forest University Health Sciences · NCT07474090Triple Negative Breast Cancer and Celecoxib. Pilot Study
Phase 2 · 1 location(s) · Université de Sherbrooke · NCT07104266A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)
Phase 1/Phase 2 · 1 location(s) · Shenzhen Majory Biotechnology Co., Ltd. · NCT07208149A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor
Phase 1/Phase 2 · 10 location(s) · A2 Biotherapeutics Inc. · NCT06682793Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC
Phase 2 · 1 location(s) · University of Utah · NCT05464082A Clinical Study of Albumin-bound Paclitaxel/Granulocyte-based Therapy for Recurrent/Metastatic Breast Cancer
NA · 2 location(s) · JIANG LONGWEI · NCT06496724Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)
Phase 3 · 1 location(s) · Japanese Foundation for Cancer Research · NCT07190443Preoperative Partial Breast Reirradiation and Repeat Breast-conserving Surgery in Patients With Recurrent Breast Cancer:
Phase 2 · 1 location(s) · Amsterdam UMC, location VUmc · NCT06640881A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Trip
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06471205
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.